Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

International Journal of Clinical Oncology ◽

10.1007/s10147-015-0943-z ◽

2016 ◽

Vol 21 (4) ◽

pp. 705-712 ◽

Cited By ~ 3

Author(s):

Yuji Miyamoto ◽

Akihito Tsuji ◽

Hiroaki Tanioka ◽

Soichiro Maekawa ◽

Hirofumi Kawanaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

S-1 and CPT-11 plus ramucirumab (IRIS+Rmab) as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: A multicenter phase II study in Japan (N-DOCC-F-C-1701)

Annals of Oncology ◽

10.1093/annonc/mdx659.049 ◽

2017 ◽

Vol 28 ◽

pp. x56

Author(s):

K. Kobayashi ◽

M. Morita ◽

S. Ito ◽

Y. Inoue ◽

I. Yamaguchi ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

Multicenter phase II study of irinotecan as second line chemotherapy in metastatic colorectal cancer after prior exposure to infusional 5-FU based chemotherapy

European Journal of Cancer ◽

10.1016/s0959-8049(01)81572-0 ◽

2001 ◽

Vol 37 ◽

pp. S293

Author(s):

P. Schöffski ◽

U. Vanhoefer ◽

H. Kirchner ◽

G. Trenn ◽

C. Bokemeyer ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Prior Exposure ◽

Second Line ◽

Multicenter Phase ◽

S-1 and CPT-11 Plus Ramucirumab (IRIS+Rmab) as Second-Line Chemotherapy for Patients with Oxaliplatin-Refractory Metastatic Colorectal Cancer (mCRC): A Multicenter Phase II Study in Japan (N-DOCC-F-C-1701)

The Kurume Medical Journal ◽

10.2739/kurumemedj.ms661007 ◽

2019 ◽

Vol 66 (1) ◽

pp. 43-47

Author(s):

KAZUMA KOBAYASHI ◽

MICHI MORITA ◽

SAEKO FUKUI ◽

SHINICHIRO ITO ◽

YUSUKE INOUE ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

Multicenter Phase II Study of Gemcitabine and Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Colorectal Cancer Patients Pretreated with 5-Fluorouracil plus Irinotecan

Oncology ◽

10.1159/000092956 ◽

2006 ◽

Vol 70 (2) ◽

pp. 106-114 ◽

Cited By ~ 13

Author(s):

N. Ziras ◽

A. Potamianou ◽

I. Varthalitis ◽

K. Syrigos ◽

S. Tsousis ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

Colorectal Cancer Patients ◽

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-012-1875-1 ◽

2012 ◽

Vol 69 (6) ◽

pp. 1641-1645 ◽

Cited By ~ 41

Author(s):

Alberto Zaniboni ◽

Enrico Aitini ◽

Sandro Barni ◽

Daris Ferrari ◽

Stefano Cascinu ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Pancreatic Cancer ◽

Second Line ◽

Multicenter Phase ◽

Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study

Journal of Korean Medical Science ◽

10.3346/jkms.2005.20.6.966 ◽

2005 ◽

Vol 20 (6) ◽

pp. 966 ◽

Cited By ~ 10

Author(s):

Jin Ho Baek ◽

Jong Gwang Kim ◽

Sang Kyun Sohn ◽

Dong Hwan Kim ◽

Kyu Bo Lee ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

Pretreated Patients ◽

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

Investigational New Drugs ◽

10.1007/s10637-010-9400-z ◽

2010 ◽

Vol 29 (5) ◽

pp. 1038-1044 ◽

Cited By ~ 9

Author(s):

José María Viéitez ◽

Manuel Valladares ◽

Ignacio Peláez ◽

Luis de Sande González ◽

Jesús García-Foncillas ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Randomized Phase Ii ◽

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3583 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3583-3583 ◽

Cited By ~ 22

Author(s):

A. L. A. Fields ◽

D. A. Rinaldi ◽

C. A. Henderson ◽

C. J. Germond ◽

L. Chu ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Second Line ◽

Open Label ◽

Second Line Therapy ◽

Multicenter Phase ◽

Line Therapy

Updated results of the FIRIS study: A phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.3562 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 3562-3562 ◽

Cited By ~ 6

Author(s):

H. Baba ◽

K. Muro ◽

H. Yasui ◽

Y. Shimada ◽

A. Tsuji ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Second Line ◽